Normal P0 glycoprotein rescues pathological effects of mutant P0 in a transgenic mouse model of CMT1B

S. C. Previtali, A. Quattrini, M. Fasolini, D. Imperiale, C. Panzeri, A. Villa, A. Messing, N. Canal, L. Wrabetz, M. L. Feltri

Research output: Contribution to journalArticle

Abstract

Gene therapy will constitute the treatment of choice in the next few years for many hereditary diseases. Protein replacement will be highly effective in all those disorders due to a loss of function mechanism. Unfortunately, many hereditary disorders are caused by gain of function mechanism. The dominant negative or toxic effect of a mutated protein could render the efficacy of replacement therapy unpredictable. Point mutations affecting the extracellular domain of P0 glycoprotein cause hereditary neuropathies such as Charcot-Marie-Tooth 1B (CMT1B). The majority of these patients are heterozygous for the mutation and the disorder segregates dominantly. Hence, most of these neuropathies are the consequence of a gain of function mechanism. We created a transgenic line of mice that manifested behavioral, electrophysiological, and morphological abnor- malities typical of subtypes of human CMT1B. The transgene encodes for a wild-type P0 with a myc epitope tag at the mature amino-terminus (P0-myc). The P0-myc allele likely behaves as a dominant-negative and is responsible for myelin uncompaction and abnormal myelin folding of the peripheral nerve. Interestingly, increasing the dosage of wild-type P0 by genetic crosses ameliorates the phenotype of these mice. The number of uncompacted or excessive folded fibers is progressively reduced. Unfortunately, the efficacy of this approach is limited by a threshold for P0 over-dosage, which causes developmental dysmyelination when it exceeds by 50% the normal level. Dysmyelination is severe, dose-dependent, and affects the early events of nerve development. In conclusion, we demonstrate for the first time that protein replacement may also benefit CMT neuropathies associated with a gain of function mechanism. Nevertheless, P0 dosage is still limiting for gene therapy. However, since dysmyelination is the consequence of the early excessive expression of P0, the increase in P0 dosage may have a reduced effect in the adult nerve.

Original languageEnglish
JournalNeurological Sciences
Volume21
Issue number4 SUPPL.
Publication statusPublished - 2000

Fingerprint

Myelin P0 Protein
Transgenic Mice
Tooth
Myelin Sheath
Genetic Therapy
Genetic Crosses
Inborn Genetic Diseases
Proteins
Poisons
Transgenes
Peripheral Nerves
Point Mutation
Epitopes
Alleles
Phenotype
Mutation
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Normal P0 glycoprotein rescues pathological effects of mutant P0 in a transgenic mouse model of CMT1B. / Previtali, S. C.; Quattrini, A.; Fasolini, M.; Imperiale, D.; Panzeri, C.; Villa, A.; Messing, A.; Canal, N.; Wrabetz, L.; Feltri, M. L.

In: Neurological Sciences, Vol. 21, No. 4 SUPPL., 2000.

Research output: Contribution to journalArticle

Previtali, SC, Quattrini, A, Fasolini, M, Imperiale, D, Panzeri, C, Villa, A, Messing, A, Canal, N, Wrabetz, L & Feltri, ML 2000, 'Normal P0 glycoprotein rescues pathological effects of mutant P0 in a transgenic mouse model of CMT1B', Neurological Sciences, vol. 21, no. 4 SUPPL..
Previtali, S. C. ; Quattrini, A. ; Fasolini, M. ; Imperiale, D. ; Panzeri, C. ; Villa, A. ; Messing, A. ; Canal, N. ; Wrabetz, L. ; Feltri, M. L. / Normal P0 glycoprotein rescues pathological effects of mutant P0 in a transgenic mouse model of CMT1B. In: Neurological Sciences. 2000 ; Vol. 21, No. 4 SUPPL.
@article{9799abafd5b04d1aac5fd20ba3162f4e,
title = "Normal P0 glycoprotein rescues pathological effects of mutant P0 in a transgenic mouse model of CMT1B",
abstract = "Gene therapy will constitute the treatment of choice in the next few years for many hereditary diseases. Protein replacement will be highly effective in all those disorders due to a loss of function mechanism. Unfortunately, many hereditary disorders are caused by gain of function mechanism. The dominant negative or toxic effect of a mutated protein could render the efficacy of replacement therapy unpredictable. Point mutations affecting the extracellular domain of P0 glycoprotein cause hereditary neuropathies such as Charcot-Marie-Tooth 1B (CMT1B). The majority of these patients are heterozygous for the mutation and the disorder segregates dominantly. Hence, most of these neuropathies are the consequence of a gain of function mechanism. We created a transgenic line of mice that manifested behavioral, electrophysiological, and morphological abnor- malities typical of subtypes of human CMT1B. The transgene encodes for a wild-type P0 with a myc epitope tag at the mature amino-terminus (P0-myc). The P0-myc allele likely behaves as a dominant-negative and is responsible for myelin uncompaction and abnormal myelin folding of the peripheral nerve. Interestingly, increasing the dosage of wild-type P0 by genetic crosses ameliorates the phenotype of these mice. The number of uncompacted or excessive folded fibers is progressively reduced. Unfortunately, the efficacy of this approach is limited by a threshold for P0 over-dosage, which causes developmental dysmyelination when it exceeds by 50{\%} the normal level. Dysmyelination is severe, dose-dependent, and affects the early events of nerve development. In conclusion, we demonstrate for the first time that protein replacement may also benefit CMT neuropathies associated with a gain of function mechanism. Nevertheless, P0 dosage is still limiting for gene therapy. However, since dysmyelination is the consequence of the early excessive expression of P0, the increase in P0 dosage may have a reduced effect in the adult nerve.",
author = "Previtali, {S. C.} and A. Quattrini and M. Fasolini and D. Imperiale and C. Panzeri and A. Villa and A. Messing and N. Canal and L. Wrabetz and Feltri, {M. L.}",
year = "2000",
language = "English",
volume = "21",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Normal P0 glycoprotein rescues pathological effects of mutant P0 in a transgenic mouse model of CMT1B

AU - Previtali, S. C.

AU - Quattrini, A.

AU - Fasolini, M.

AU - Imperiale, D.

AU - Panzeri, C.

AU - Villa, A.

AU - Messing, A.

AU - Canal, N.

AU - Wrabetz, L.

AU - Feltri, M. L.

PY - 2000

Y1 - 2000

N2 - Gene therapy will constitute the treatment of choice in the next few years for many hereditary diseases. Protein replacement will be highly effective in all those disorders due to a loss of function mechanism. Unfortunately, many hereditary disorders are caused by gain of function mechanism. The dominant negative or toxic effect of a mutated protein could render the efficacy of replacement therapy unpredictable. Point mutations affecting the extracellular domain of P0 glycoprotein cause hereditary neuropathies such as Charcot-Marie-Tooth 1B (CMT1B). The majority of these patients are heterozygous for the mutation and the disorder segregates dominantly. Hence, most of these neuropathies are the consequence of a gain of function mechanism. We created a transgenic line of mice that manifested behavioral, electrophysiological, and morphological abnor- malities typical of subtypes of human CMT1B. The transgene encodes for a wild-type P0 with a myc epitope tag at the mature amino-terminus (P0-myc). The P0-myc allele likely behaves as a dominant-negative and is responsible for myelin uncompaction and abnormal myelin folding of the peripheral nerve. Interestingly, increasing the dosage of wild-type P0 by genetic crosses ameliorates the phenotype of these mice. The number of uncompacted or excessive folded fibers is progressively reduced. Unfortunately, the efficacy of this approach is limited by a threshold for P0 over-dosage, which causes developmental dysmyelination when it exceeds by 50% the normal level. Dysmyelination is severe, dose-dependent, and affects the early events of nerve development. In conclusion, we demonstrate for the first time that protein replacement may also benefit CMT neuropathies associated with a gain of function mechanism. Nevertheless, P0 dosage is still limiting for gene therapy. However, since dysmyelination is the consequence of the early excessive expression of P0, the increase in P0 dosage may have a reduced effect in the adult nerve.

AB - Gene therapy will constitute the treatment of choice in the next few years for many hereditary diseases. Protein replacement will be highly effective in all those disorders due to a loss of function mechanism. Unfortunately, many hereditary disorders are caused by gain of function mechanism. The dominant negative or toxic effect of a mutated protein could render the efficacy of replacement therapy unpredictable. Point mutations affecting the extracellular domain of P0 glycoprotein cause hereditary neuropathies such as Charcot-Marie-Tooth 1B (CMT1B). The majority of these patients are heterozygous for the mutation and the disorder segregates dominantly. Hence, most of these neuropathies are the consequence of a gain of function mechanism. We created a transgenic line of mice that manifested behavioral, electrophysiological, and morphological abnor- malities typical of subtypes of human CMT1B. The transgene encodes for a wild-type P0 with a myc epitope tag at the mature amino-terminus (P0-myc). The P0-myc allele likely behaves as a dominant-negative and is responsible for myelin uncompaction and abnormal myelin folding of the peripheral nerve. Interestingly, increasing the dosage of wild-type P0 by genetic crosses ameliorates the phenotype of these mice. The number of uncompacted or excessive folded fibers is progressively reduced. Unfortunately, the efficacy of this approach is limited by a threshold for P0 over-dosage, which causes developmental dysmyelination when it exceeds by 50% the normal level. Dysmyelination is severe, dose-dependent, and affects the early events of nerve development. In conclusion, we demonstrate for the first time that protein replacement may also benefit CMT neuropathies associated with a gain of function mechanism. Nevertheless, P0 dosage is still limiting for gene therapy. However, since dysmyelination is the consequence of the early excessive expression of P0, the increase in P0 dosage may have a reduced effect in the adult nerve.

UR - http://www.scopus.com/inward/record.url?scp=33845312713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845312713&partnerID=8YFLogxK

M3 - Article

VL - 21

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 4 SUPPL.

ER -